Table 1.
UPDRS outcome data and levodopa equivalent daily dose (LEDD) for all 40 patients
| Baseline score, mean | Post-DBS score, mean | Mean percent improvement (95%C.I.) | |
|---|---|---|---|
| UPDRS-III | 55.2 | 24.7 | 55% (46–65) |
| Rigidity | 10.8 | 4.4 | 59% (46–72) |
| Bradykinesia | 21.0 | 8.7 | 58% (45–72) |
| Tremor | 9.7 | 2.8 | 71% (47–95) |
| Axial | 10.2 | 6.5 | 36% (17–55) |
| UPDRS-I | 13.4 | 10.0 | 26% (11–40) |
| UPDRS-II | 19.8 | 15.1 | 24% (12–35) |
| UPDRS-IV | 8.8 | 5.2 | 41% (25–57) |
| LEDD/mg | 1233 | 825 | 32% (24–40) |
Mean baseline pre-operative OFF-medication and post-operative ON-stimulation/OFF-medication UPDRS part III total score and subscores for rigidity, bradykinesia, tremor and axial features are shown. Mean baseline pre-operative and post-operative scores for UPDRS parts I, II and IV and LEDD are also presented. All comparisons between baseline and post-DBS scores were highly significant (p < 0.001; paired t-test)